Israeli medical imaging vendor Elscint is preparing to begin commercialshipments of its Coincidence Detection (CODE) high-energy imagingtechnique after receiving 510(k) clearance from the Food and DrugAdministration last month. Elscint joins ADAC
Israeli medical imaging vendor Elscint is preparing to begin commercialshipments of its Coincidence Detection (CODE) high-energy imagingtechnique after receiving 510(k) clearance from the Food and DrugAdministration last month. Elscint joins ADAC Laboratories andPicker International in being able to market coincidence detection,which is used to image high-energy radioisotopes like fluorodeoxyglucose.
Elscint will offer CODE on its premium variable-angle VariCamgamma camera, with a list price under $200,000, according to RichardBrown, marketing manager at Elscint's U.S. subsidiary in Hackensack,NJ. Elscint is also debating whether to offer CODE to its installedbase of older Helix opposable-angle cameras. Helix cameras wouldhave to be upgraded with new detectors and acquisition racks,however, which might make a CODE upgrade prohibitively expensive.
Elscint will offer CODE in two configurations: CODE 3 employsa 3/8-inch crystal, while CODE 5 uses a 5/8-inch version. Lastmonth's 510(k) clearance applies to CODE 3, and a supplementaryapplication will be filed for CODE 5, according to Brown.
CODE should help increase VariCam sales, which have paced Elscint'snuclear medicine division to record sales levels, according topresident and CEO Jonathan Adereth. CODE will also improve profitmargins in the nuclear medicine line, which in the past has sufferedfrom declining profitability, Adereth said.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.